MDT

95.62

+0.66%↑

VEEV

283

-3.27%↓

A

141.9

+0.66%↑

HQY

91.19

+0.35%↑

TLRY

1.55

+1.31%↑

MDT

95.62

+0.66%↑

VEEV

283

-3.27%↓

A

141.9

+0.66%↑

HQY

91.19

+0.35%↑

TLRY

1.55

+1.31%↑

MDT

95.62

+0.66%↑

VEEV

283

-3.27%↓

A

141.9

+0.66%↑

HQY

91.19

+0.35%↑

TLRY

1.55

+1.31%↑

MDT

95.62

+0.66%↑

VEEV

283

-3.27%↓

A

141.9

+0.66%↑

HQY

91.19

+0.35%↑

TLRY

1.55

+1.31%↑

MDT

95.62

+0.66%↑

VEEV

283

-3.27%↓

A

141.9

+0.66%↑

HQY

91.19

+0.35%↑

TLRY

1.55

+1.31%↑

Search

MannKind Corp

Closed

SectorHealthcare

5.47 2.63

Overview

Share price change

24h

Current

Min

5.44

Max

5.51

Key metrics

By Trading Economics

Income

-12M

668K

Sales

-1.8M

77M

P/E

Sector Avg

46.364

36.442

Profit margin

0.873

Employees

403

EBITDA

-17M

9.7M

Recommendations

By TipRanks

Recommendations

Strong Buy

12 Months Forecast

+93.24% upside

Dividends

By Dow Jones

Next Earnings

6 Nov 2025

Market Stats

By TradingEconomics

Market Cap

373M

1.6B

Previous open

2.84

Previous close

5.47

News Sentiment

By Acuity

100%

0%

358 / 371 Healthcare

Technical Score

By Trading Central

Confidence

Bullish Evidence

MannKind Corp Chart

Past performance is not a reliable indicator of future results.

Related News

19 Oct 2025, 20:00 UTC

Acquisitions, Mergers, Takeovers

Infratil Agrees to NZ$437.7 Million Deal to Raise Contact Energy Stake

19 Oct 2025, 23:44 UTC

Market Talk

Gold Edges Lower Amid Signs of U.S.-China Trade Tensions Easing -- Market Talk

19 Oct 2025, 23:37 UTC

Market Talk

New Zealand's Core CPI Keeps Rate Cut Hopes Alive -- Market Talk

19 Oct 2025, 23:36 UTC

Market Talk

Nikkei May Rise, Tracking Wall Street Gains -- Market Talk

19 Oct 2025, 23:36 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

19 Oct 2025, 23:09 UTC

Market Talk

Could Rio Tinto, BHP Ally to Defend Iron-Ore Pricing Power? -- Market Talk

19 Oct 2025, 22:41 UTC

Acquisitions, Mergers, Takeovers

Luxury Fashion House Kering Confirms Beauty Deal With L'Oréal -- Barrons.com

19 Oct 2025, 22:30 UTC

Earnings

Stock Futures Rise Ahead of Major Week of Earnings -- Barrons.com

19 Oct 2025, 22:18 UTC

Market Talk

Gold at $5,000 on Cards as Investors Get Comfortable -- Market Talk

19 Oct 2025, 21:50 UTC

Market Talk

Infratil's Contact Stake Buy May Require Bigger Asset Sales -- Market Talk

19 Oct 2025, 21:15 UTC

Market Talk

Investors Need to Change Narrative Toward Scales -- Market Talk

19 Oct 2025, 19:34 UTC

Acquisitions, Mergers, Takeovers

Infratil's Contact Shareholding to Rise to 14.3% When Deal Completes

19 Oct 2025, 19:34 UTC

Acquisitions, Mergers, Takeovers

Infratil to Issue New Shares Worth NZ$218.8 Million to TECT at NZ$12.43 Each

19 Oct 2025, 19:33 UTC

Acquisitions, Mergers, Takeovers

Infratil Part-Funding Purchase of Contact Energy Stake With NZ$218.8 Million of Existing Debt

19 Oct 2025, 19:32 UTC

Acquisitions, Mergers, Takeovers

Infratil Acquiring Additional Contact Energy Stake for NZ$8.95/Share

19 Oct 2025, 19:32 UTC

Acquisitions, Mergers, Takeovers

Infratil Acquiring Contact Energy Stake for NZ$437.7 Million

19 Oct 2025, 19:31 UTC

Acquisitions, Mergers, Takeovers

Infratil Acquiring TECT Holdings's Shareholding in Contact Energy

19 Oct 2025, 19:31 UTC

Acquisitions, Mergers, Takeovers

Infratil to Acquire Additional 4.92% Stake in Contact Energy

19 Oct 2025, 16:29 UTC

Earnings

Elon Musk Pay Drama Heats Up Ahead of Tesla Earnings -- Barrons.com

19 Oct 2025, 11:14 UTC

Earnings

Zijin Mining 3Q Oper Income CNY86.49B; up 8.1% on Year>2899.HK

19 Oct 2025, 11:14 UTC

Earnings

Zijin Mining: Higher Sales of Gold, Copper Supported Results >2899.HK

19 Oct 2025, 11:14 UTC

Earnings

Zijin Mining 3Q Net CNY14.57B; up 57.1% on Year>2899.HK

18 Oct 2025, 13:30 UTC

Acquisitions, Mergers, Takeovers

Deal Expected to Value Unit at Roughly $4B, Sources Say -- WSJ

18 Oct 2025, 13:30 UTC

Acquisitions, Mergers, Takeovers

Deal Could Be Announced as Soon as Next Week, Sources Say -- WSJ

18 Oct 2025, 13:30 UTC

Acquisitions, Mergers, Takeovers

Gucci Owner Kering Nears $4 Billion Sale of Beauty Unit to L'Oréal -- WSJ

18 Oct 2025, 13:30 UTC

Acquisitions, Mergers, Takeovers

Gucci Parent Kering in Talks to Sell Beauty Business to L'Oréal, Sources Say -- WSJ

18 Oct 2025, 08:20 UTC

Market Talk

Tech, Media & Telecom Roundup: Market Talk

17 Oct 2025, 23:25 UTC

Acquisitions, Mergers, Takeovers

New Zealand's 'Golden Visa' Targets the Affluent in Search of Plan B -- Barrons.com

17 Oct 2025, 22:15 UTC

Market Talk

Ulta's CFO Appointment Seen Supporting Growth -- Market Talk

17 Oct 2025, 21:15 UTC

Market Talk

Greece Expected to Post Overall Budgetary Surplus This Year -- Market Talk

Peer Comparison

Price change

MannKind Corp Forecast

Price Target

By TipRanks

93.24% upside

12 Months Forecast

Average 10.57 USD  93.24%

High 15 USD

Low 8 USD

Based on 7 Wall Street analysts offering 12 month price targets forMannKind Corp - Dist in the last 3 months.

Rating Consensus

By TipRanks

Strong Buy

7 ratings

7

Buy

0

Hold

0

Sell

Technical Score

By Trading Central

4.079 / 4.323Support & Resistance

Short Term

Bullish Evidence

Intermediate Term

Bearish Evidence

Long Term

Weak Bearish Evidence

Sentiment

By Acuity

358 / 371 Healthcare

News Sentiment

Very Strong Bearish Evidence

Volatility

Below average

News Volume (RCV)

Below average

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

$

About MannKind Corp

MannKind Corporation, a biopharmaceutical company, focuses on the development and commercialization of inhaled therapeutic products for endocrine and orphan lung diseases in the United States. It offers Afrezza, an inhaled insulin used to improve glycemic control in adults with diabetes, and the V-Go wearable insulin delivery device, which provides continuous subcutaneous infusion of insulin in adults. The company's product pipeline also includes Tyvaso DPI (Treprostinil), an inhalation powder for the treatment of pulmonary arterial hypertension and pulmonary hypertension associated with interstitial lung disease; MNKD-101, a nebulized formulation of clofazimine, for the treatment of severe chronic and recurrent pulmonary infections, including nontuberculous mycobacterial lung disease; MNKD-201, a dry-powder formulation of nintedanib, for the treatment of idiopathic pulmonary fibrosis (IPF). In addition, it has collaboration and license agreement with United Therapeutics Corporation for development, regulatory, and commercial activities of Tyvaso DPI; co-promotion agreement with Vertice Pharma to promote Thyquidity; and collaboration agreement with Thirona to evaluate the therapeutic for the treatment of pulmonary fibrosis. Further, the company has supply and distribution agreement with Biomm S.A. for the commercialization of Afrezza in Brazil; and license and distribution agreement with Cipla Ltd. for the marketing and distribution of Afrezza in India. MannKind Corporation was incorporated in 1991 and is headquartered in Danbury, Connecticut.
help-icon Live chat